Shepherd Veterinary Software vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
YC-backed cloud veterinary PMS designed from the ground up by veterinarians for modern clinic workflow efficiency. San Francisco CA; founded 2018;
About
Shepherd Veterinary Software is a San Francisco-based cloud veterinary practice management system backed by Y Combinator and designed from the ground up for the operational workflow needs of modern veterinary clinics. Founded in 2018 by veterinarians and technologists who experienced firsthand the frustrations of legacy practice management systems, Shepherd built a clean, intuitive platform that integrates appointment scheduling, medical records, treatment tracking, invoicing, and inventory management into a unified workflow optimized for the pace and multitasking demands of a busy veterinary practice. Unlike older systems that were designed around a desktop paradigm and adapted for web, Shepherd was built as a cloud-native application from day one.\n\nShepherd's clinical workflow design reflects its founding team's veterinary experience. The platform's whiteboard feature provides a real-time view of every patient in the clinic—which exam room they are in, what treatments have been administered, what orders are outstanding, and who is responsible for each task. This "at a glance" operational view reduces the communication overhead between veterinarians, technicians, and receptionists that leads to errors and delays in busy multi-doctor practices. The treatment sheet auto-populates charges based on administered treatments, reducing the billing leakage common in practices where staff must manually add charges from memory.\n\nShepherd targets independent veterinary practices and small veterinary groups in the United States, competing with established systems including IDEXX's AVImark, ezyVet, Cornerstone, and ImproMed in the veterinary practice management market. The company differentiates on user experience quality, cloud-native reliability, and the speed of its development cycle—as a well-funded startup with a modern tech stack, Shepherd can ship product improvements significantly faster than legacy software vendors. Shepherd has gained traction primarily through referrals within veterinary professional networks and targeted digital marketing reaching veterinary clinic owners and practice managers.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.